2023 World Conference on Lung Cancer (Posters)-EP11.03. The Efficacy of Immunotherapy and Chemoimmunotherapy in STK11, KEAP1 & KRAS Gene Mutations in Advanced Non-small Cell Lung Cancer (NSCLC)

EP11.03. The Efficacy of Immunotherapy and Chemoimmunotherapy in STK11, KEAP1 & KRAS Gene Mutations in Advanced Non-small Cell Lung Cancer (NSCLC) - PDF(Abstract)

Back to course

Pdf Summary

This presentation at WCLC 2023 discusses the efficacy of immunotherapy and chemoimmunotherapy in patients with advanced non-small cell lung cancer (NSCLC) who have mutations in the STK11, KEAP1, and KRAS genes. While there has been progress in using programmed death-ligand 1 (PD-L1) inhibitors to improve progression-free survival (PFS) and overall survival (OS) in advanced NSCLC, most patients do not respond to immune checkpoint inhibitors (ICI). The ability to predict which patients will respond to immunotherapy is limited. <br /><br />The researchers conducted a systematic search of randomized control clinical trials investigating immunotherapy alone or with chemotherapy, chemotherapy alone, and chemoimmunotherapy in treatment-naïve advanced NSCLC patients. They specifically focused on studies that provided data on KRAS mutation, STK11 loss, and/or KEAP1 loss. They analyzed the data using meta-analyses and meta-regression analysis.<br /><br />The results showed that patients with KRAS mutation and STK11 and/or KEAP1 loss responded poorly to PD-L1 therapy. They had shorter disease-free survival (DFS) and/or overall survival compared to other patients. The researchers concluded that future trials of immunotherapy and chemoimmunotherapy should stratify patients based on these mutations. They also suggest the development of novel immunotherapy approaches to improve outcomes for this group of patients.<br /><br />This presentation highlights the importance of understanding the genetic characteristics of patients with advanced NSCLC in order to tailor treatment strategies. Identifying specific genetic mutations, such as KRAS, STK11, and KEAP1, can help predict treatment response and guide the development of targeted therapies. Further research and clinical trials are warranted to improve outcomes for patients with these mutations.

Asset Subtitle

Tony Cheung

Meta Tag

Speaker Tony Cheung

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

WCLC 2023

immunotherapy

chemoimmunotherapy

non-small cell lung cancer

NSCLC

STK11 gene

KEAP1 gene

KRAS gene

PD-L1 inhibitors

immune checkpoint inhibitors